1
FEATURED STORY |
 |
||
 |
Three Studies Presented at 43rd EASL Showed
Higher SVR for Peginterferon Alfa-2a (PEGASYS) Plus Ribavirin Than Peginterferon Alfa-2b Plus Ribavirin in Treating Hepatitis C
|
|
|
2
FEATURED STORY |
|
||
|
Roche’s Investigational Hepatitis C Polymerase Inhibitor, R1626
Demonstrated Significant End-of-Treatment Response in Phase IIa Study
|
|
|
3
FEATURED STORY |
|
||
|
IMPORTANT: Drug Warning Update
to PEGASYS and COPEGUS Package Inserts
|
|
|
4
FEATURED STORY |
|
||
|
Impact of Cumulative Drug Exposure in Genotype 1 Patients
K. Rajender Reddy, MD
|
|
|
5
FEATURED STORY |
|
||
|
Treatment with PEGASYS® / COPEGUS™ Provides
Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron®/Ribavirin
|
|
|
Hepatology Quick Links:
| Press Releases | Important Drug Update | ||
| News | |||
| Treatment Algorithm | |||
| Prescribing Information | |||
| Clinical Trials |
The Latest Hepatology News
|
|
| ||||||||
|
|
| ||||||||
